The 7investing Podcast

7investing's Watch List of New Ideas introduces stocks that we've never formally recommended yet are worth considering as future scorecard additions. You can think of this as our pipeline of new investment opportunities. This month, 7investing CEO Simon Erickson is adding two new two European companies: BE Semiconductor (OTC: BESIY) and Novo Nordisk (NYSE: NVO). He describes why Besi's advanced packaging leadership makes it a natural winner from innovative new chip designs, and why Novo Nordisk is still in the earliest innings of introducing Ozempic as a treatment for obesity. 7investing makes its formal recommendations available through its Premium Membership. To see all of our stock market recommendations through a 100% free 7 day trial, join today at 7investing.com/subscribe.

Fertility benefits company Progyny's (Nasdaq: PGNY) stock is selling off 33% in today's trading session after announced it's losing its largest customer who accounted for 13% of the previous year's revenue. This customer was unnamed, but it's most likely Amazon. Even though Progyny has historically had nearly 100% client retention and receives excellent net promoter scores, this could be a red flag for investors. 7investing CEO Simon Erickson shares his thoughts about the company's previous struggles, the Alabama Supreme Court's recent ruling about IVF embryos, and how investors should think about Progyny's stock going forward.

Upstart Holdings (Nasdaq: UPST) has been one of the investing world's most volatile stocks. Since peaking at $400 per share in late 2021, its stock has fallen more than 90% and sits at just $35 today. Many believe this roller coaster ride has followed the American macroeconomy. The Zero Interest Rate policy directly following COVID was replaced by the fastest rise in interest rates the United States had ever seen in 2022. Yet Upstart might be seeing signs of life. It issued optimistic revenue guidance for the upcoming Q3 and Q4. Not coincidently, this aligns with the Fed suggesting that a rate cut is most definitely on the table. But investors aren't out of the woods just yet. In today's episode, 7investing CEO Simon Erickson describes the fundamental challenges Upstart still faces and why it doesn't have the most shareholder-friendly leadership team. See more of our coverage on Upstart and 200 other publicly-traded companies at 7investing.com!

Simon Erickson, the CEO of 7investing and a savvy market analyst, shares a striking about-face on Celsius Holdings. He discusses the critical red flags that shifted his view from bullish to bearish. Key topics include the challenges Celsius faces in a competitive energy drink market, uncertainties around ownership after a major investor’s passing, and implications of Pepsi's reduced orders. With changing consumer preferences in the mix, Erickson highlights why long-term investors should reconsider Celsius' future prospects.

Wolfspeed (NYSE: WOLF) is one of Wall Street's ultimate battleground stocks. As the world's largest provider of silicon carbide, it supplies one of the most necessary materials for next-generation Electric Vehicles. Based on the size of its potential market and the long-term supply agreements with large automakers, its stock appears to be extremely undervalued. Yet Wolfspeed is also facing some serious headwinds, specifically in government-supported financing to construct its fabs and lagging demand for EVs from consumers. It's fallen short of its explicitly-stated guidance, which has hurt its credibility with investors. So is Wolfspeed's stock a howling buy or a whimpering sell? In today's episode, 7investing Simon Erickson describes several of the opportunities and challenges that Wolfspeed faces. He discusses several financial and operational updates, the crucial difference between "design-ins" and "design-wins", and what investors should be watching most closely. 7investing issues Conviction Ratings for all of the stocks in our coverage universe. Ranging from "Strong Buy" to "Sell" and all points in between, these represent how confident we are about investing in a particular stock right now. To see our current Conviction Rating for Wolfspeed (which might actually surprise you), sign up for our premium membership at ⁠7investing.com/subscribe⁠. Use promo code "september" at checkout to waive our signup fee and to get your first week entirely free!

Tesla always gives investors plenty to talk about! In today's show, 7investing CEO Simon Erickson describes 3 key takeaways from the company's second quarter report: - The all-time high in regulatory credits, driven by attractive financing rates and political uncertainty - The Energy business recognizing an all-time high in revenue and growing 100% in year-over-year comparisons - A production and deliveries update on the Model S, X, and Cybertruck. Overall, Simon believes Tesla's stock is only worth $104 per share "as a car company" but is worth up to $650 per share "as an AI company". https://7investing.com/articles/tesla-the-ai-company-is-worth-645-per-share-heres-what-makes-the-stock-a-buy-today/ Join our free email list to have our investing insights delivered to your inbox every week: 7investing.com/email

The "organ transplant as a service" market is taking the medical world by storm. How long can the accelerated growth rates continue? TransMedics (Nasdaq: TMDX) is a unique company you might have never heard of. But it’s playing an important role in saving the lives of thousands of Americans every year. As the creator of its patented Organ Care System (OCS), it is the only FDA-approved technology to transport lungs, hearts, and livers in the United States. When a registered donor is recently deceased, TransMedics’ OCS keeps their organs functional long enough to be transplanted into another patient who is badly in need. The transplant must happen as quickly and as efficiently as possible, since this is a matter of life and death. In today's episode, 7investing CEO Simon Erickson describes this fast-growing new market and why it's eagerly being embraced by organ transplant centers. He also highlights two key risks that investors should consider when sizing up TMDX as a long-term opportunity.

United Therapeutics (Nasdaq: UTHR) is a very smart, very innovative, and very profitable company. First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry. In today's show, 7investing CEO Simon Erickson introduces United Therapeutics, describing why the company was created and its five commercially-approved drugs. He also explains how its four synthetic organ programs could disrupt the entire organ transplant market. See why United Therapeutics is a stock that should be on your radar. To join our free email list, visit 7investing.com/email.

Innovative Industrial Properties is America's only publicly-traded REIT who's exclusively focused on the cannabis industries. It buys cannabis-growing facilities and then rents the spaces out to tenants through triple-net leases. Business was booming in the zero-interest rate economy, with IIP's committed capital skyrocketing 60-fold from $30 million in 2016 to $2 billion in 2023. But with interest rates rising and a shaky economy, growth is much slower these days. The stock currently pays a dividend of 6.7%. That's much higher than money market funds and bonds, with the possibility of rising if the Fed cuts rates in 2024. https://7investing.com/company-update/innovative-industrial-properties-patience-is-a-virtue/ See our current conviction rating on IIPR -- as well as all of the stocks in our universe of coverage -- by starting your 7investing membership today. Visit 7investing.com/subscribe and use promo code "IIPR" at checkout to get your first week for absolutely free!

Tesla (Nasdaq: TSLA) is one of the market’s most unique battleground stocks. People either love it or they hate it, the financial media's commentary is either euphoric or miserable, and institutional price targets have ranged everywhere from $10 to $2,000. For the past two weeks, 7investing CEO Simon Erickson has been building a very detailed discounted cash flow for Tesla. He's put all emotions (and social interaction) aside and has let the numbers do the talking -- to develop his most-likely estimate of Tesla's future revenues, operating costs, and capital expenses through the year 2040. Furthermore, a large part of the Tesla equation lies in the optionality offered by its visionary (and yet eccentric) CEO Elon Musk. Musk has several options of where he could lead Tesla into its future, including full self-driving software subscriptions, autonomous commercial trucks, an on-demand Robotaxi network, or a thousand other AI-based projects. Yet even with so many potential destinations, the Tesla we know today is still primarily a car company. 92% of its revenue currently comes from selling, leasing, and servicing battery-powered electric vehicles. IN THIS PART 1 OF 2, Simon describes how he came up with an estimate of $104 per share for Tesla as a car company. The company is aggressively building Gigafactories and ramping up the production of new models, but is also constrained on pricing and by rising competition in China. Disclosure: Options are not suitable for all investors and carry significant risk. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. Certain complex options strategies carry additional risk. There are additional costs associated with option strategies that call for multiple purchases and sales of options, such as spreads, straddles, among others, as compared with a single option trade. Prior to buying or selling an option, investors must read and understand the “Characteristics and Risks of Standardized Options”, also known as the options disclosure document (ODD) which can be found at: www.theocc.com/company-information/documents-and-archives/options-disclosure-documentSupporting documentation for any claims will be furnished upon request. If you are enrolled in our Options Order Flow Rebate Program, The exact rebate will depend on the specifics of each transaction and will be previewed for you prior to submitting each trade. This rebate will be deducted from your cost to place the trade and will be reflected on your trade confirmation. Order flow rebates are not available for non-options transactions. To learn more, see our Fee Schedule, Order Flow Rebate FAQ, and Order Flow Rebate Program Terms & Conditions.Options can be risky and are not suitable for all investors. See the Characteristics and Risks of Standardized Options to learn more.All investing involves the risk of loss, including loss of principal. Brokerage services for US-listed, registered securities, options and bonds in a self-directed account are offered by Open to the Public Investing, Inc., member FINRA & SIPC. See public.com/#disclosures-main for more information.